目标:尽管全球范围内有关迷幻药物的政策有所进步,我们对现实世界迷幻使用及其在国际司法管辖区的差异的理解仍然有限。我们实施了全球迷幻调查(GPS),以捕获有关迷幻消费者特征的信息,access,以及世界各地的使用模式。
方法:GPS于2023年春季在线对使用(d)迷幻药的英语成年人(≥21岁)进行了在线管理。我们将调查响应分类为主要集水区(加拿大/美国,欧洲/英国,澳大利亚/新西兰,所有其他)。我们使用描述性和双变量统计数据来表征消费者的社会人口统计特征,迷幻的访问来源,和使用模式。我们使用多项逻辑回归研究了迷幻使用模式的区域差异。
结果:我们分析了来自包括加拿大/美国在内的85个国家的6379份回复(n=4434),欧洲/英国(n=771),澳大利亚/新西兰(n=864),和其他(n=310)。psilocybin,LSD,MDMA是最常用的迷幻药,个人成长是所有集水区最常见的使用动机。迷幻使用模式存在显著的地区差异,包括使用的迷幻药类型(例如,相对于加拿大/美国,欧洲/英国和澳大利亚/新西兰的ibogaine使用较少),使用频率(例如,相对于加拿大/美国,澳大利亚/新西兰的使用频率较低),使用动机(例如,相对于加拿大/美国,欧洲/英国和其他国家的治疗用途较少),和给药方案的类型(例如,更多“微量”-加拿大/美国的剂量)。
结论:在这个来自世界各地的成年迷幻消费者的大样本中,以提高生活为中心的罕见迷幻药使用很常见。受访者表示倾向于通过质量控制来源进行合法访问。访问和使用模式的司法管辖区差异可能反映了特定地区的法规和传统做法。进一步的研究应探索机会,通过将研究翻译成多种语言并纳入文化反思,增加非白人受访者在迷幻研究中的代表性。以社区为基础的学习发展。
OBJECTIVE: Despite advancements in policies governing psychedelic substances globally, our understanding of real-world psychedelic use and its variations across international jurisdictions remains limited. We implemented the Global Psychedelic Survey (GPS) to capture information about psychedelic consumer characteristics, access, and usage patterns around the world.
METHODS: The GPS was administered online in Spring 2023 to English-speaking adults (≥21 years) who use(d) psychedelics. We categorized survey responses into major catchment regions (Canada/US, Europe/UK, Australia/NZ, All Other). We used descriptive and bivariable statistics to characterize consumers\' socio-demographic characteristics, psychedelic access sources, and usage patterns. We examined regional differences in psychedelic use patterns using multinomial logistic regression.
RESULTS: We analyzed 6379 responses from 85 countries including Canada/US (n = 4434), Europe/UK (n = 771), Australia/NZ (n = 864), and Other (n = 310). Psilocybin, LSD, and MDMA were the most used psychedelics and personal growth was the most common use motive across all catchments. There were significant regional differences in psychedelic use patterns, including types of psychedelics used (e.g., less ibogaine use in Europe/UK and Australia/NZ relative to Canada/US), frequency of use (e.g., lower frequency use in Australia/NZ relative to Canada/US), motivations for use (e.g., less therapeutic use in Europe/UK and Other relative to Canada/US), and types of dosing regimens (e.g., more \"micro\"-dosing in Canada/US).
CONCLUSIONS: In this large sample of adult psychedelic consumers from regions around the world, infrequent psychedelic use centered around life enhancement was common. Respondents indicated preference for legal access via quality-controlled sources. Jurisdictional differences in access and usage patterns likely reflect region-specific regulations and traditional practices. Further research should explore opportunities to increase representation of non-White respondents in psychedelic research via translation of studies into several languages and incorporation of culturally reflective, community-based study development.